Connected Diabetes Device Market Size, Share & Forecast 2026–2035
What Is the Connected Diabetes Device Market Size?
The global Connected Diabetes Device market was valued at USD 21.5 Billion in 2025 and is projected to grow from USD 24.2 Billion in 2026 to USD 70.4 Billion by 2035, at a CAGR of 12.6% from 2026–2035.
Connected Diabetes Device Market Key Takeaways
According to Healthcare Industry Insights analysis, the market's trajectory from USD 24.2 Billion in 2026 to USD 70.4 Billion by 2035 will be shaped by the shift from standalone glucose meters toward integrated sensor, pump, and data-platform ecosystems that clinicians and payers increasingly expect.
What Does the Connected Diabetes Device Market Encompass?
The Connected Diabetes Device market covers wireless-enabled glucose sensors, connected insulin pumps and smart pens, and the cloud data platforms, dosing algorithms, and interoperability services that transmit diabetes data to patients, caregivers, and clinicians. Structurally, the market has evolved from isolated meter readings toward closed-loop and remote-monitoring workflows, with regulatory and reimbursement frameworks increasingly tied to documented device data.
Parameter Description
| Parameter | Details |
|---|---|
| Market Size in 2025 | USD 21.5 Billion |
| Market Size in 2026 | USD 24.2 Billion |
| Revenue Forecast in 2035 | USD 70.4 Billion |
| Growth Rate | CAGR of 12.6% from 2026 to 2035 |
| Analysis Period | 2025–2035 |
| Base Year Considered | 2025 |
| Forecast Period | 2026–2035 |
| Market Size Estimation | Revenue (USD Billion) |
| Companies Profiled | 20 Profiled |
| Countries Covered | 38 Countries |
| Market Share | Available for Top 10 Companies |
Key Emerging Trends in the Connected Diabetes Device Market
Based on research conducted by Healthcare Industry Insights, we found that four structural trends are reshaping product development, sourcing, and stakeholder engagement across the Connected Diabetes Device industry.
Growth Drivers, Restraints & Opportunities
The following interactive matrix outlines the primary forces shaping the Connected Diabetes Device market through 2035, categorized by qualitative impact level, geographic relevance, and projected timeline. Type in the search box to filter by driver, restraint, or opportunity.
| Factors ▲ | Type | Qualitative Impact | Geographic Focus | Timeline |
|---|---|---|---|---|
| Broad CGM and automated insulin delivery reimbursement | DRIVER | High | Sustains North American revenue base and demand anchor | 2026–2035 |
| Rising diabetes prevalence in China, India, and Japan | DRIVER | High | Fuels Asia-Pacific absolute value expansion at 12.6% CAGR | 2026–2035 |
| Falling sensor and component costs with local manufacturing scale-up | DRIVER | Medium | Broadens access in price-sensitive markets | 2026–2035 |
| Price-based tendering and heterogeneous HTA processes in Europe | RESTRAINT | Medium | Constrains pace of European reimbursement expansion | 2026–2035 |
| Limited reimbursement and small addressable base in parts of Africa | RESTRAINT | Medium | Limits uptake outside Gulf state programs | 2026–2035 |
Which Reimbursement Mandates Serve as Demand Anchors?
Our assessment indicates that Medicare and commercial CGM coverage functions as a compliance floor and demand anchor rather than a growth engine. It stabilizes the Continuous Glucose Monitoring for Type 1 Diabetes Management segment, which holds approximately 46.0% of 2025 revenue, but its 10.5% CAGR over the 2026–2035 forecast period is lower than emerging applications, so it should be read as baseline demand.
Which Segments Act as True Growth Vectors?
Healthcare Industry Insights's analysis indicates that growth vectors are concentrated in Proprietary Software at 11.1% CAGR and Hospitals and Integrated Delivery Networks at 20.8% CAGR over the 2026–2035 forecast period. These high-CAGR segments are the growth engines of the market, while mandated coverage sustains volume without leading expansion.
What Limits Adoption in Price-Sensitive Regions?
Based on research conducted by our analysts, we found that Latin America and the Middle East & Africa face access constraints from private insurance gaps and limited public reimbursement. Latin America is nonetheless expanding at a 14.7% CAGR over the 2026–2035 forecast period as Brazil and Argentina broaden public-private procurement.
Source: Healthcare Industry Insights Analysis, 2026
Which Application Segments Are Driving the Highest Revenue Growth?
Segment Sizing: By Offering
Within the By Offering category, the Specialized Hardware: Sensors, Transmitters, Insulin Pumps and Pens segment held the dominant market share in 2025. Meanwhile, the Proprietary Software: Data Platforms, Dosing Algorithms, and Clinical Analytics segment is anticipated to be the fastest-growing, expanding at a CAGR of 17.3% during the forecast period.
| Segment Item | 2025 (USD Bn) | 2026 (USD Bn) | 2035 (USD Bn) | CAGR (2026–2035) |
|---|---|---|---|---|
| Specialized Hardware: Sensors, Transmitters, Insulin Pumps and Pens | 12.5 | 13.6 | 29.6 | 9.0% |
| Proprietary Software: Data Platforms, Dosing Algorithms, and Clinical Analytics | 5.8 | 6.9 | 28.9 | 17.3% |
| Integration and Interoperability Services: EHR Connectivity, Validation, and Regulatory Support | 3.2 | 3.7 | 11.9 | 13.9% |
| Total | 21.5 | 24.2 | 70.4 | 12.6% |
Source: Healthcare Industry Insights Analysis, 2026
Segment Sizing: By Application
Within the By Application category, the Continuous Glucose Monitoring for Type 1 Diabetes Management segment held the dominant market share in 2025. Meanwhile, the Remote Patient Monitoring and Clinician Data Review for Type 2 Diabetes Management segment is anticipated to be the fastest-growing, expanding at a CAGR of 15.0% during the forecast period.
| Segment Item | 2025 (USD Bn) | 2026 (USD Bn) | 2035 (USD Bn) | CAGR (2026–2035) |
|---|---|---|---|---|
| Continuous Glucose Monitoring for Type 1 Diabetes Management | 9.9 | 10.9 | 26.8 | 10.5% |
| Connected Insulin Delivery (Automated and Smart Pumps and Pens) for Insulin-Dependent Patients | 6.0 | 6.8 | 21.1 | 13.4% |
| Remote Patient Monitoring and Clinician Data Review for Type 2 Diabetes Management | 3.4 | 4.0 | 14.1 | 15.0% |
| Gestational and Pediatric Diabetes Connected Care Programs | 2.2 | 2.5 | 8.4 | 14.4% |
| Total | 21.5 | 24.2 | 70.4 | 12.6% |
Source: Healthcare Industry Insights Analysis, 2026
Segment Sizing: By End-User
Within the By End-User category, the Individual Patients and Home-Care Users (Direct-to-Patient Purchasers and Pharmacy Channels) segment held the dominant market share in 2025. Meanwhile, the Hospitals, Endocrinology Clinics, and Integrated Delivery Networks segment is anticipated to be the fastest-growing, expanding at a CAGR of 17.9% during the forecast period.
| Segment Item | 2025 (USD Bn) | 2026 (USD Bn) | 2035 (USD Bn) | CAGR (2026–2035) |
|---|---|---|---|---|
| Individual Patients and Home-Care Users (Direct-to-Patient Purchasers and Pharmacy Channels) | 13.1 | 14.6 | 31.8 | 9.0% |
| Hospitals, Endocrinology Clinics, and Integrated Delivery Networks | 5.8 | 7.2 | 31.8 | 17.9% |
| Payers, Government Health Programs, and Employer-Sponsored Diabetes Management Services | 2.6 | 2.4 | 6.8 | 12.3% |
| Total | 21.5 | 24.2 | 70.4 | 12.6% |
Source: Healthcare Industry Insights Analysis, 2026
Key Market Segments
The complete segmentation hierarchy used throughout this report. Click a category to view its sub-segments.
Growth Opportunities
Our analysis shows that three forward-looking opportunities stand out for stakeholders positioning within this market over the forecast period.
Where Can Vendors Capture Unmet Type 2 Demand?
Remote monitoring for insulin-treated Type 2 patients, growing at 15.0% CAGR, represents a whitespace opportunity beyond the Type 1 cohort. Vendors can package clinician data review with device subscriptions to serve this expanding base.
How Can Platform Providers Monetize Interoperability?
Proprietary Software at 17.3% CAGR and Integration and Interoperability Services at 13.9% CAGR offer whitespace for vendors that align with EHR connectivity standards. Certified integration pathways can unlock hospital and clinic contracts within the forecast horizon.
Which Asia-Pacific Markets Offer Scale Entry?
China, growing at 16.4% CAGR to USD 5.5 Billion by 2035, and India, growing at 15.7% CAGR, present scale-entry opportunities for locally manufactured sensors and lower-cost connected platforms.
Investment Opportunities
Capital Inflows
Capital is flowing toward data platforms and clinical analytics, where Proprietary Software is projected to grow at 17.3% CAGR over the 2026–2035 forecast period. Investors are favoring companies that pair device sales with recurring data services. This shift supports valuation expansion for platform-centric vendors.
Infrastructure
Hospital and integrated delivery network investment in connected care infrastructure, at 20.8% CAGR, creates demand for EHR-integrated device pipelines. Infrastructure spending on interoperability and secure data handling is becoming a prerequisite for scaled deployment.
ESG
Connected devices reduce supply-chain waste from disposable meters and support remote management that lowers clinic visit burden. ESG-oriented investors are increasingly evaluating diabetes device portfolios on access equity and data-governance practices.
SWOT Analysis
Our assessment indicates that the following strengths, weaknesses, opportunities, and threats characterize the competitive position of the Connected Diabetes Device heading into 2035.
Established reimbursement in North America and a mature hardware base anchor revenue, with North America holding approximately 46.8% of 2025 global revenue. Diversified sensor, pump, and software portfolios support cross-selling across the care pathway.
Heterogeneous European HTA processes and price-based tendering slow reimbursement timing. Hardware-dependent revenue concentration leaves vendors exposed to component cost volatility.
Proprietary Software at 17.3% CAGR and Hospitals at 20.8% CAGR signal strong expansion in data-centric and clinical channels. Asia-Pacific's 16.0% regional CAGR offers high-volume growth.
Data privacy, ownership, and secondary-use regulation may constrain platform business models. Pricing pressure from tendering and limited reimbursement in parts of Latin America and Africa could compress margins.
Access the Full Market Report
38 Countries · 20 Profiled · 10-year forecast with YoY data tables · Free Excel data file included
Regional Outlook
Click a region to explore its key national markets and growth drivers.
North America was valued at USD 10.06 Billion in 2025 and estimated at USD 11.18 Billion in 2026, reaching USD 28.86 Billion by 2035 at a 11.1% CAGR (2026–2035). Early Medicare and commercial reimbursement for CGM and automated insulin delivery sustains its dominance, though its share dilutes as Asia-Pacific accelerates. High device penetration and established clinical workflows underpin steady expansion.
United States
CanadaEurope was valued at USD 5.2 Billion in 2025 and estimated at USD 5.8 Billion in 2026, reaching USD 16.2 Billion by 2035 at a 12.1% CAGR (2026–2035). National systems in Germany, the UK, and France are widening reimbursement for type 1 and insulin-treated type 2 patients. Price-based tendering and heterogeneous HTA processes moderate the pace of uptake across member states.
Germany
United Kingdom
FranceAsia-Pacific was valued at USD 4.1 Billion in 2025 and estimated at USD 4.8 Billion in 2026, reaching USD 18.3 Billion by 2035 at a 16.0% CAGR (2026–2035). Rising diabetes prevalence in China, India, and Japan, paired with local manufacturing and falling sensor costs, drives the fastest regional expansion. Infrastructure readiness varies, but national programs are steadily broadening device access.
China
India
Japan
South Korea
AustraliaLatin America was valued at USD 1.07 Billion in 2025 and estimated at USD 1.23 Billion in 2026, reaching USD 4.22 Billion by 2035 at a 14.7% CAGR (2026–2035). Growing private insurance coverage and public-private procurement in Brazil and Argentina extend access beyond urban, high-income cohorts. Regulatory alignment and procurement capacity remain the key variables shaping regional pace.
Brazil
ArgentinaMiddle East & Africa was valued at USD 1.07 Billion in 2025 and estimated at USD 1.19 Billion in 2026, reaching USD 2.82 Billion by 2035 at a 10.1% CAGR (2026–2035). It is the smallest region in the 2026 snapshot, with Gulf national diabetes programs supporting steady uptake. A limited addressable base and constrained reimbursement outside the Gulf keep growth measured.
Saudi Arabia
UAE
South AfricaCompetitive Landscape
We observed that a small group of established device manufacturers commands much of the hardware revenue, while software and platform providers occupy a fragmented but fast-expanding layer. Our assessment indicates that this structure rewards vendors able to bundle hardware with data services.
Connected Diabetes Device Competitive Insights
| Dimension | Description |
|---|---|
| Market Structure | Moderately consolidated, with a handful of CGM and pump leaders alongside specialized software and platform providers |
| Innovation Focus | Sensor longevity, automated dosing algorithms, interoperability with EHR systems, and remote clinician review |
| M&A Activity | Active tuck-in acquisitions of software and data-platform capabilities by device manufacturers |
Source: Healthcare Industry Insights Analysis, 2026
Market Concentration
We observed that a small group of established device manufacturers commands much of the hardware revenue, while software and platform providers occupy a fragmented but fast-expanding layer. Our assessment indicates that this structure rewards vendors able to bundle hardware with data services.
Innovation Priorities
Our findings suggest that innovation is concentrated on dosing-algorithm automation, sensor accuracy, and seamless EHR connectivity. Vendors that standardize data outputs gain advantages in hospital and payer procurement.
Partnership and Channel Models
During our market evaluation, we noticed that device makers increasingly partner with digital health platforms and pharmacy channels to reach direct-to-patient buyers, which represent the largest 2025 end-user pool.
Competitive Pressure from Tendering
We found that price-based tendering in Europe and cost-sensitive procurement in emerging markets intensify competition, pushing vendors toward scale manufacturing and localized production.
Key Market Players in the Connected Diabetes Device
Key companies active in the global Connected Diabetes Device include:
Latest Connected Diabetes Device Industry Developments
We found that recent product launches within the Connected Diabetes Device are concentrated on key technological advancements, reflecting the industry's broader transition.
| Date | Summary | Source |
|---|---|---|
| September 2025 | iCoDE: The iCoDE-2 Steering Committee held its final meeting on September 18, 2025 to advance standards for integrating connected diabetes device data into the EHR. | Official Announcement |
| January 2025 | Glooko released updated software notes for its Glooko for Professional Use clinical platform. | Official Announcement |
| January 2025 | Glooko released updated software notes for its Glooko for Personal Use patient-facing application. | Official Announcement |
| January 2025 | Diabetes Technology Society: The Diabetes Technology Society published the iCoDE-2 standard project page describing connected device data integration into electronic health records. | Official Announcement |
| January 2025 | Journals: Research published on integration of connected diabetes device data into the electronic health record. | Official Announcement |
| January 2025 | Nature: Publication addressing accelerating AI in clinical care, relevant to connected diabetes data analytics. | Official Announcement |
| January 2025 | PMC: Publication examining data privacy, ownership, and secondary use of clinical data from connected devices. | Official Announcement |
| January 2025 | Journals: Publication on principles of interoperability of diabetes devices. | Official Announcement |
Source: Healthcare Industry Insights Analysis, 2026
Key Benefits for Connected Diabetes Device Stakeholders
Stakeholder
Device manufacturers can use the Specialized Hardware base, which holds approximately 58.1% of 2025 revenue, as a platform for cross-selling data services. Aligning products with interoperability standards shortens hospital procurement cycles and supports durable recurring revenue.
Stakeholder
Investors gain exposure to a market projected to reach USD 70.4 Billion by 2035 at a 12.6% CAGR over the 2026–2035 forecast period. Prioritizing high-CAGR software and clinical-channel exposure, rather than mandated hardware volume alone, aligns portfolios with the market's growth vectors.
Stakeholder
Platform and algorithm providers can capture Integration and Interoperability Services at 13.9% CAGR and Proprietary Software at 17.3% CAGR. Certified EHR connectivity and clear data-governance frameworks differentiate offerings in payer and hospital contracting.
Conclusion and Recommendations
Long-Term Outlook
The market is set to expand from USD 24.2 Billion in 2026 to USD 70.4 Billion by 2035. Mandated reimbursement will anchor baseline demand, while growth shifts toward data-centric and clinical-channel expansion through the 2026–2035 forecast period.
Strategic Positioning Recommendations
Vendors should bundle hardware with interoperable software and clinician review services. Positioning around EHR connectivity and data governance will strengthen hospital and payer access.
Investment Attractiveness
Investment attractiveness is strongest in Proprietary Software at 17.3% CAGR and Hospitals and Integrated Delivery Networks at 20.8% CAGR. The Absolute Dollar Opportunity of USD 46.2 Billion between 2026 and 2035 signals substantial capital room.
Market Shifts and Key Risks
Data privacy and secondary-use rules, along with European tendering pressure, represent the principal risks. Monitoring regulatory shifts in consent and data ownership will be essential for platform strategies.
Growth Pathways
Primary growth pathways lie in Remote Patient Monitoring for Type 2 diabetes at 15.0% CAGR and Asia-Pacific absolute value expansion at 12.6% CAGR. Mandated CGM coverage should be treated as a demand anchor that sustains the revenue base.
Frequently Asked Questions
Consolidated Source Table
| Source / Organization | URL |
|---|---|
| iCoDE Official Announcement | https://pmc.ncbi.nlm.nih.gov/articles/PMC12546080/ |
| Glooko Official Announcement | https://support.glooko.com/hc/en-us/articles/360007533157-Release-Notes-Glooko-for-Professional-Use |
| Glooko Official Announcement | https://support.glooko.com/hc/en-us/articles/360007574978-Release-Notes-Glooko-for-Personal-Use |
| Diabetes Technology Society Official Announcement | https://www.diabetestechnology.org/icode/icode2.shtml |
| Journals Official Announcement | https://journals.sagepub.com/doi/abs/10.1177/19322968231207888 |
| Nature Official Announcement | https://www.nature.com/articles/s41746-026-03094-3 |
| Pmc Official Announcement | https://pmc.ncbi.nlm.nih.gov/articles/PMC13243303/ |
| Journals Official Announcement | https://journals.sagepub.com/doi/abs/10.1177/19322968241268235 |
Methodology Note: Market sizing figures are HII industry-derived estimates based on triangulated supply-side manufacturer revenue analysis, demand-side consumption assessment, and macro-level trade and investment tracking across publicly available corporate disclosures, government statistics, and regulatory filings. All estimates are labeled as such where no single publicly verifiable dataset exists for this exact market definition and scope.
Summarize This Report:
You May Also Like
Custom Market Research Services
We will customise the research for you, in case the report listed above does not meet with your exact requirements. Get 30% free customisation on this report.